2026-01-11, Sun.

Top Stories       Business       Culture & Life       Science & Technology       World

Lecture

Notification

 

NEWS > Science & Technology


Famenity's Brain Factor-7¢ç Gains Global Momentum as Clinically Validated Ingredient for Cognitive Health

Date: 2026-01-03

SEOUL -- Famenity Co., Ltd., a South Korean research and development company specializing in functional ingredients for health supplements, said that its Brain Factor-7® (BF-7®) is drawing attention among global brands seeking clinical-grade cognitive-support ingredients.

BF-7®, a silk-peptide complex, is backed by over 12 independent human studies across the entire lifespan, from children and students to adults and seniors. The findings collectively confirm BF-7®’s benefits for memory, learning ability, cognitive performance, focus, and mental resilience, establishing BF-7® as one of the most comprehensively validated natural cognitive-health ingredients available today. BF-7® is supported by multiple global regulatory recognitions, led first by its listing as a U.S. FDA New Dietary Ingredient (NDI). It is also licensed through Health Canada (NPN), acknowledged by the Ministry of Food and Drug Safety (MFDS) in Korea as an Individually Recognized Functional Ingredient, and certified Halal, making it suitable for the global market. As demand in North America and Europe shifts toward clean-label, non-stimulant nootropics with real clinical evidence, BF-7® stands out thanks to its derivation: a low-molecular-weight silk fibroin peptide complex refined through Famenity’s proprietary enzymatic hydrolysis.

Recent interest has been further driven by BF-7®’s mechanistic profile. Research indicates that BF-7® strengthens neuronal network functioning, supports acetylcholine modulation, reduces oxidative stress, and helps protect neurons from environmental and psychological stressors—mechanistic advantages increasingly valued by supplement formulators and functional-beverage developers.

Finished products containing BF-7® are already distributed across the United States, Canada, Europe, and Asia, reflecting strong commercial acceptance and global scalability. Beyond BF-7®, Famenity has built a broad portfolio of clinically grounded functional ingredients. These include MS-10®, a patented botanical complex supporting women’s menopausal comfort; MR-10®, a men’s vitality and performance formulation; GinsaMin®, a U.S. FDA NDI-listed ginseng-derived compound; TamiSense® (Live EGF), a premium bioactive solution utilizing live EGF for skin regeneration; YES-10®, a mental-wellness ingredient targeting stress balance; and TEES-10®, a dental and oral-health complex. This diverse ingredient platform—spanning cognitive health, women’s and men’s health, skin renewal, mental wellness, and oral care—highlights Famenity’s position as a science-driven innovator in global functional material development.

The company stated that with the global brain-health market rapidly expanding across all age groups, it remains committed to delivering safe, validated, and industry-ready functional ingredients to international partners.



 to the Top List of News

Cellular IoT Connections to Reach 5.9 Billion by 2035
AI Power Surge and Energy Transition Push Global Project Finance into a New Era
Skyhigh Security Boosts DSPM to Aid DPDPA Compliance, Strengthening Data Protection Across Asia Pacific
Cleveland Clinic and Baszucki Group Partner to Advance Landmark Brain Study Using Metabolic Health Markers
Lenovo Defines Next Era of Hybrid AI With Personalized, Perceptive, Proactive Portfolio at Tech World CES 2026
Lenovo Debuts AI Super Agent and Next-Gen Mobile, Gaming, Consumer, Commercial Innovations at CES 2026
CES 2026: GIGABYTE is ¡°AI Forward,¡± Showcasing AI Factory, Physical AI, and Agentic AI Solutions

 

Abu Dhabi¡¯s TII Launches Falcon-H1 Arabic, Establishing the World¡¯s ...
Rising Demand for AI Power Accelerates S-Fuelcell¡¯s Grid-Free, On-Sit...
NetApp Expands EMEA, LATAM Reach with Willem Hendrickx Appointment as ...
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-N...
Semiconductor Quarterly Revenue Surpasses $200bn for the First Time as...
From Pilots to Profit: NTT DATA's 2026 Global AI Report Shows How Top ...
AI Won¡¯t Transform Mobility Without Unprecedented Collaboration, Stud...

 

 

60, Gamasanro 27gil, Guro-gu, Seoul, Korea, e-mail: news@newsji.com

Copyright, NEWSJI NETWORK.

.